Could antiretrovirals be treating EBV in MS? A case report
Name
1-s2.0-S2211034818300828-main.pdf
Size
375.38 KB
Format
Adobe PDF
Checksum (MD5)
2b1d873ba7799448dd34fc4550f8e348
Author(s)
Drosu, Natalia
Edelman, Elazer R
Housman, David E
Date Issued
May 2018
Journal
Multiple Sclerosis and Related Disorders
Citation
Drosu, Natalia C., Elazer R. Edelman, and David E. Houseman. “Could Antiretrovirals Be Treating EBV in MS? A Case Report.” Multiple Sclerosis and Related Disorders, vol. 22, May 2018, pp. 19–21. © 2018 The Authors
Version
Final published version
Abstract
We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved significant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improvements in lesion burden detected by MRI. All improvements have been sustained for more than three years. This response may be related to the action of zidovudine as a known inhibitor of EBV lytic DNA replication, suggesting future directions for clinical investigation. Keywords: Multiple sclerosis, Epstein-Barr virus
MIT Department
Institute for Medical Engineering and Science
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.msard.2018.02.029
